FDC Ltd
- P/E
- 17.9x
- 52-week range
- 312.95 – 473.6
- ROE
- 12%
- ROCE
- 17%
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its products include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen Sodium, Miconazole Nitrate, Timolol Maleate, Amoxycillin + Clavulanic Acid, Rupatadine Fumarate, Salbutamol Sulphate, Kaolin Light/ Pectin, among others. The Company’s product offerings cover an extensive range of categories, including anti-infectives, gastrointestinal treatments, ophthalmic, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, respiratory care, gynecology, dermatology and analgesics. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →FDC Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.9 against a typical 33.2: cheaper than most peers (1st = cheapest).50th of 220
- Sales growth+3.1% against a typical +15.6% from a year earlier.142nd of 197
- Profit growth+9.1% against a typical +18.9% from a year earlier.97th of 160
- Share price, 3 months−14.8% against a typical −2%.165th of 200
Latest announcements
Exchange filings and their impact on the company.
- Strong Q2 with 21% sales growth plus Rs 120 cr buyback at Rs 500, a 49% premium, supports earnings and price.
FDC reported Q2 FY27 consolidated revenue of Rs 572.1 crore, up 21% from last year, and net profit of Rs 49.1 crore, up from Rs 28.4 crore, with half-year profit of Rs 181.6 crore. The board also approved a Rs 120 crore share buyback of up to 24 lakh shares at Rs 500 each via tender offer, a 49% premium to the current price, with record date November 13, 2026. The buyback plus strong operating momentum should lift EPS and support the share price despite the cash payout.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Buyback | To consider buyback for equity shares |
| 5 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 27 May 2026 | Financial Results | To consider and approve the Audited Standalone & Consolidated Financial Results of the Company for Quarter and Year ended March 31, 2026 |
| 5 Feb 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended December 31, 2025, dividend and other business matters |
| 5 Nov 2025 | Financial Results/Other business matters | To consider and approve the unaudited financial results for the period ended September 30, 2025 and other business matters |
| 7 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 486 | 458 | 462 | 638 | 514 | 464 | 492 | 648 | 473 | 465 | 585 | 668 |
| Expenses | 410 | 374 | 406 | 492 | 444 | 417 | 438 | 508 | 439 | 412 | 478 | 525 |
| Operating Profit | 76 | 84 | 56 | 147 | 70 | 47 | 54 | 140 | 34 | 52 | 106 | 143 |
| OPM % | 16% | 18% | 12% | 23% | 14% | 10% | 11% | 22% | 7% | 11% | 18% | 21% |
| Other Income | 27 | 25 | 20 | 28 | 35 | 19 | 16 | 36 | 21 | 0 | 50 | 48 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 | 15 | 15 | 14 | 15 |
| Profit before tax | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 | 38 | 36 | 140 | 175 |
| Tax % | 25% | 19% | 29% | 27% | 20% | 28% | 27% | 24% | 26% | 22% | 26% | 24% |
| Net Profit | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 | 28 | 28 | 103 | 132 |
| EPS in Rs | 4.29 | 4.87 | 2.84 | 7.31 | 4.42 | 2.28 | 2.38 | 7.45 | 1.74 | 1.74 | 6.35 | 8.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 8%
- 5 Years
- 10%
- 3 Years
- 7%
- TTM
- 3%
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 16%
- TTM
- 14%
- 10 Years
- 6%
- 5 Years
- 0%
- 3 Years
- −4%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 12%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| FDC Ltd | ₹ 376.60 | — | 17.9x | — | 12% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.6x | 5.3x | 0% | 0% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94.3x | 14.8x | 0% | 0% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 75.8x | 20x | 0% | 0% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.7x | 4.2x | 0% | 0% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.6x | 3.2x | 0% | 0% |
Management
- Vishal Shah
- Chief Financial Officer
- Ameya Ashok Chandavarkar
- Chief Executive Officer - International Business, Executive Director
- Varsharani Katre
- Compliance Officer, Company Secretary
- Mohan Anand Chandavarkar
- Managing Director, Executive Director
- Nandan Mohan Chandavarkar
- Joint Managing Director, Executive Director
- Ashok Anand Chandavarkar
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.